Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) for H-pylori (Hp) infection.

被引：0
|
作者：
van der Wouden, EJ
Thijs, JC
van Zwet, AA
Kooy, A
Kleibeuker, JH
机构：
[1] Reg Publ Hlth Lab Groningen Drenthe, Groningen, Netherlands
[2] Bethesda Hosp, Hoogeveen, Netherlands
[3] Univ Groningen Hosp, Groningen, Netherlands
来源：
GASTROENTEROLOGY | 1998年 / 114卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
G1321
引用
收藏
页码：A323 / A323
页数：1
相关论文
共 50 条
  • [1] The influence of metronidazole (MET) resistance on the efficacy of two triple therapy regimens with ranitidine bismuth citrate (RBC) for H-pylori (Hp) infection
    Van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    [J]. GUT, 1998, 43 : A86 - A86
  • [2] The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection
    Van der Wouden, EJ
    Thijs, JC
    Van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (03) : 297 - 302
  • [3] Triple therapy with ranitidine-bismuth citrate, clarithromycin and metronidazole to cure clarithromycin-resistant H. pylori
    Deprez, PH
    Burette, A
    De Prez, C
    Mana, F
    Avezani, V
    Glupczynski, Y
    [J]. GASTROENTEROLOGY, 2002, 122 (04) : A65 - A65
  • [4] Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori
    Smoot, DT
    Hinds, T
    Ashktorab, H
    Jagtap, J
    Kim, KS
    Scott, VF
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (04): : 955 - 958
  • [5] Frequent metronidazole resistance without significant impact on the high cure rate of Helicobacter pylori (HP) infection by triple therapy with omeprazole (OME), metronidazole (MET), and clarithromycin (CLA)
    Peitz, U
    Nusch, A
    Tillenburg, B
    Becker, T
    Stolte, M
    Borsch, G
    Labenz, J
    [J]. GASTROENTEROLOGY, 1996, 110 (04) : A226 - A226
  • [6] Randomized comparison of ranitidine bismuth citrate (RBC)-based triple therapies for H-pylori (HP).
    Laine, L
    Estrada, R
    Trujillo, M
    Emami, S
    [J]. GASTROENTEROLOGY, 1997, 112 (04) : A192 - A192
  • [7] Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection
    Savarino, V
    Zentilin, P
    Bisso, G
    Pivari, M
    Bilardi, C
    Biagini, R
    Mele, MR
    Mansi, C
    Termini, R
    Vigneri, S
    Celle, G
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (01) : 43 - 47
  • [8] Impact of treatment duration and metronidazole resistance on H-pylori (HP) cure with omeprazole, metronidazole, and clarithromycin
    Peitz, U
    Nusch, A
    Tillenburg, B
    Starke, T
    Stolte, M
    Borsch, G
    Labenz, J
    [J]. GASTROENTEROLOGY, 1997, 112 (04) : A255 - A255
  • [9] A prospective randomized trial of one-week bismuth ranitidine citrate (RBC) triple therapies for H-pylori infection.
    Sung, JJY
    Chan, FKL
    Leung, WK
    Wu, JCY
    Suen, R
    Ling, TKW
    Lee, YT
    Cheng, AFB
    Chung, SCS
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A321 - A321
  • [10] Three months therapy with ranitidine bismuth citrate (RBC) reduces H-pylori-associated gastritis and density of H-pylori but does not cure the infection.
    Graham, DY
    Walsh, JH
    Schubert, TT
    Lanza, FL
    Peura, DA
    Peterson, W
    Riff, DS
    Yardley, J
    Ciociola, AA
    Kong, S
    Wood, D
    Webb, DD
    [J]. GASTROENTEROLOGY, 1996, 110 (04) : A122 - A122
12345